SCHEMBL835002

SCHEMBL835002

Cn1c(=O)cc(Sc2ccc(F)cc2)c2cc(F)ccc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 1/20 0.45
ATM Q13315 1/20 0.43
KDM4E B2RXH2 2/20 0.41
NQO2 P16083 1/20 0.41
POLB P06746 1/20 0.40
MEN1 O00255 1/20 0.40
HCRTR1 O43613 1/20 0.40
KMT2A Q03164 1/20 0.40
SRC P12931 1/20 0.39
BRD4 O60885 2/20 0.39
RHEB Q15382 1/20 0.39
HSD17B10 Q99714 1/20 0.38
ALDH1A1 P00352 3/20 0.37
HTT P42858 2/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSP90AA1 P07900 1/20 0.37
AKR1B1 P15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL835001 0.93 RXFP1 (0.44) RXFP1ATMKDM4ENQO2POLB
SCHEMBL835197 0.92 RXFP1 (0.49) RXFP1ATMKDM4ERHEBALDH1A1
SCHEMBL835284 0.90 RXFP1 (0.43) RXFP1ATMKDM4ENQO2POLB
SCHEMBL836028 0.88 KDM4E (0.51) RXFP1ATMKDM4ENQO2POLB
SCHEMBL835229 0.86 NQO2 (0.42) RXFP1ATMKDM4ENQO2POLB
SCHEMBL836066 0.81 RXFP1 (0.48) RXFP1ATMKDM4ENQO2POLB
SCHEMBL834994 0.77 KDM4E (0.49) RXFP1ATMKDM4ENQO2KMT2A
SCHEMBL14302623 0.76 LMNA (0.43) RXFP1ATMKDM4ENQO2POLB
SCHEMBL836059 0.76 RHEB (0.50) RXFP1KDM4ENQO2POLBMEN1
SCHEMBL829660 0.76 MEN1 (0.43) RXFP1ATMKDM4ENQO2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-8143276-B2 4-thio substituted quinoline and naphthyridine compounds XTL BIOPHARMACEUTICALS LTD. (IL) 2012-03-27 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds PRESIDIO PHARMACEUTICALS, INC. 2009-02-26 US disclosed
WO-2008024423-A2 4-THIO SUBSTITUTED QUINOLINE AND NAPHTHYRIDINE COMPOUNDS XTL BIOPHARMACEUTICALS LTD. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054477-A1 4-thio substituted quinoline and naphthyridine compounds GTF3C4, HNF4A, TENT4A RXFP1 4782/4885ATM 4371/4885KDM4E 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.